The world-class, low-cost gene editing solution named "BIRSA 101", in honour of Bhagwan Birsa Munda, remembered as a great ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

New research shows a therapy that’s been used for cancer patients may help people with lupus go into remission.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...

The sandwich therapy showed a 2-year overall survival rate of 97% and a leukemia-free survival rate of 72% in Ph-negative ...

DENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had ...

TARA-002, a cell-based therapy by Protara Therapeutics, shows promising results in treating lymphatic malformations in ...

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

Century Therapeutics, Inc. (NASDAQ: IPSC) has unveiled its first program targeting Type 1 diabetes, introducing an engineered ...